New NSAID Targets and Derivatives for Colorectal Cancer Chemoprevention

  • Heather N. Tinsley
  • William E. Grizzle
  • Ashraf Abadi
  • Adam Keeton
  • Bing Zhu
  • Yaguang Xi
  • Gary A. Piazza
Part of the Recent Results in Cancer Research book series (RECENTCANCER, volume 191)


Clinical and preclinical studies provide strong evidence that nonsteroidal anti-inflammatory drugs (NSAIDs) can prevent numerous types of cancers, especially colorectal cancer. Unfortunately, the depletion of physiologically important prostaglandins due to cyclooxygenase (COX) inhibition results in potentially fatal toxicities that preclude the long-term use of NSAIDs for cancer chemoprevention. While studies have shown an involvement of COX-2 in colorectal tumorigenesis, other studies suggest that a COX-independent target may be at least partially responsible for the antineoplastic activity of NSAIDs. For example, certain NSAID derivatives have been identified that do not inhibit COX-2 but have demonstrated efficacy to suppress carcinogenesis with potential for reduced toxicity. A number of alternative targets have also been reported to account for the tumor cell growth inhibitory activity of NSAIDs, including the inhibition of cyclic guanosine monophosphate phosphodiesterases (cGMP PDEs), generation of reactive oxygen species (ROS), the suppression of the apoptosis inhibitor protein, survivin, and others. Here, we review several promising mechanisms that are being targeted to develop safer and more efficacious NSAID derivatives for colon cancer chemoprevention.


Familial Adenomatous Polyposis Inhibit Tumor Cell Growth Colon Tumor Cell Carboxylic Acid Moiety Colon Tumorigenesis 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.



Funding provided by NIH grants R01 CA131378 and R01 CA148817 and a UAB Breast Cancer SPORE grant.


  1. Alberts DS et al (1995) Do NSAIDs exert their colon cancer chemoprevention activities through the inhibition of mucosal prostaglandin synthetase? J Cell Biochem Suppl 22:18–23CrossRefPubMedGoogle Scholar
  2. Altieri DC (2003a) Survivin in apoptosis control and cell cycle regulation in cancer. Prog Cell Cycle Res 5:447–452PubMedGoogle Scholar
  3. Altieri DC (2003b) Survivin and apoptosis control. Adv Cancer Res 88:31–52CrossRefPubMedGoogle Scholar
  4. Ambrosini G, Adida C, Altieri DC (1997) A novel anti-apoptosis gene, survivin, expressed in cancer and lymphoma. Nat Med 3(8):917–921CrossRefPubMedGoogle Scholar
  5. Arber N et al (2006) Celecoxib for the prevention of colorectal adenomatous polyps. N Engl J Med 355(9):885–895CrossRefPubMedGoogle Scholar
  6. Baek SJ, Horowitz JM, Eling TE (2001a) Molecular cloning and characterization of human nonsteroidal anti-inflammatory drug-activated gene promoter. Basal transcription is mediated by Sp1 and Sp3. J Biol Chem 276(36):33384–33392CrossRefPubMedGoogle Scholar
  7. Baek SJ et al (2001b) Cyclooxygenase inhibitors regulate the expression of a TGF-beta superfamily member that has proapoptotic and antitumorigenic activities. Mol Pharmacol 59(4):901–908PubMedGoogle Scholar
  8. Baek SJ et al (2002) Dual function of nonsteroidal anti-inflammatory drugs (NSAIDs): inhibition of cyclooxygenase and induction of NSAID-activated gene. J Pharmacol Exp Ther 301(3):1126–1131CrossRefPubMedGoogle Scholar
  9. Baron JA et al (2006) A randomized trial of rofecoxib for the chemoprevention of colorectal adenomas. Gastroenterology 131(6):1674–1682CrossRefPubMedGoogle Scholar
  10. Beavo JA (1995) Cyclic nucleotide phosphodiesterases: functional implications of multiple isoforms. Physiol Rev 75(4):725–748PubMedGoogle Scholar
  11. Bertagnolli MM et al (2006) Celecoxib for the prevention of sporadic colorectal adenomas. N Engl J Med 355(9):873–884CrossRefPubMedGoogle Scholar
  12. Carmell MA et al (2002) The Argonaute family: tentacles that reach into RNAi, developmental control, stem cell maintenance, and tumorigenesis. Genes Dev 16(21):2733–2742CrossRefPubMedGoogle Scholar
  13. Carter CA, Ip MM, Ip C (1989) A comparison of the effects of the prostaglandin synthesis inhibitors indomethacin and carprofen on 7,12-dimethylbenz[a]anthracene-induced mammary tumorigenesis in rats fed different amounts of essential fatty acid. Carcinogenesis 10(8):1369–1374CrossRefPubMedGoogle Scholar
  14. Chakraborti AK et al (2010) Progress in COX-2 inhibitors: a journey so far. Curr Med Chem 17(15):1563–1593CrossRefPubMedGoogle Scholar
  15. Chan TA (2002) Nonsteroidal anti-inflammatory drugs, apoptosis, and colon-cancer chemoprevention. Lancet Oncol 3(3):166–174CrossRefPubMedGoogle Scholar
  16. de Mello MC, Bayer BM, Beaven MA (1980) Evidence that prostaglandins do not have a role in the cytostatic action of anti-inflammatory drugs. Biochem Pharmacol 29(3):311–318CrossRefPubMedGoogle Scholar
  17. DuBois RN et al (1998) The nuclear eicosanoid receptor, PPARgamma, is aberrantly expressed in colonic cancers. Carcinogenesis 19(1):49–53CrossRefPubMedGoogle Scholar
  18. Eberhart CE et al (1994) Up-regulation of cyclooxygenase 2 gene expression in human colorectal adenomas and adenocarcinomas. Gastroenterology 107(4):1183–1188PubMedGoogle Scholar
  19. Elder DJ et al (1997) Induction of apoptotic cell death in human colorectal carcinoma cell lines by a cyclooxygenase-2 (COX-2)-selective nonsteroidal anti-inflammatory drug: independence from COX-2 protein expression. Clin Cancer Res 3(10):1679–1683PubMedGoogle Scholar
  20. Erickson BA et al (1999) The effect of selective cyclooxygenase inhibitors on intestinal epithelial cell mitogenesis. J Surg Res 81(1):101–107CrossRefPubMedGoogle Scholar
  21. Esquela-Kerscher A, Slack FJ (2006) Oncomirs–microRNAs with a role in cancer. Nat Rev Cancer 6(4):259–269CrossRefPubMedGoogle Scholar
  22. Frein D et al (2005) Redox regulation: a new challenge for pharmacology. Biochem Pharmacol 70(6):811–823CrossRefPubMedGoogle Scholar
  23. Fujita T et al (1998) Size- and invasion-dependent increase in cyclooxygenase 2 levels in human colorectal carcinomas. Cancer Res 58(21):4823–4826PubMedGoogle Scholar
  24. Genestra M (2007) Oxyl radicals, redox-sensitive signalling cascades and antioxidants. Cell Signal 19(9):1807–1819CrossRefPubMedGoogle Scholar
  25. Giardiello FM et al (1993) Treatment of colonic and rectal adenomas with sulindac in familial adenomatous polyposis. N Engl J Med 328(18):1313–1316CrossRefPubMedGoogle Scholar
  26. Grosch S et al (2001) COX-2 independent induction of cell cycle arrest and apoptosis in colon cancer cells by the selective COX-2 inhibitor celecoxib. Faseb J 15(14):2742–2744PubMedGoogle Scholar
  27. Halliwell B (2007) Oxidative stress and cancer: have we moved forward? Biochem J 401(1):1–11CrossRefPubMedGoogle Scholar
  28. Hanif R et al (1996) Effects of nonsteroidal anti-inflammatory drugs on proliferation and on induction of apoptosis in colon cancer cells by a prostaglandin-independent pathway. Biochem Pharmacol 52(2):237–245CrossRefPubMedGoogle Scholar
  29. Harris RE (2009) Cyclooxygenase-2 (cox-2) blockade in the chemoprevention of cancers of the colon, breast, prostate, and lung. Inflammopharmacology 17(2):55–67CrossRefPubMedGoogle Scholar
  30. Hoffman WH et al (2002) Transcriptional repression of the anti-apoptotic survivin gene by wild type p53. J Biol Chem 277(5):3247–3257CrossRefPubMedGoogle Scholar
  31. Huang GL et al (2009) Clinical significance of miR-21 expression in breast cancer: SYBR-Green I-based real-time RT-PCR study of invasive ductal carcinoma. Oncol Rep 21(3):673–679PubMedGoogle Scholar
  32. Huang L et al (2010) Phospho-sulindac (OXT-922) inhibits the growth of human colon cancer cell lines: a redox/polyamine-dependent effect. Carcinogenesis 31(11):1982–1990CrossRefPubMedGoogle Scholar
  33. Kalgutkar AS et al (2000) Ester and amide derivatives of the nonsteroidal antiinflammatory drug, indomethacin, as selective cyclooxygenase-2 inhibitors. J Med Chem 43(15):2860–2870CrossRefPubMedGoogle Scholar
  34. Kalgutkar AS et al (2002) Amide derivatives of meclofenamic acid as selective cyclooxygenase-2 inhibitors. Bioorg Med Chem Lett 12(4):521–524CrossRefPubMedGoogle Scholar
  35. Kardosh A et al (2005) Multitarget inhibition of drug-resistant multiple myeloma cell lines by dimethyl-celecoxib (DMC), a non-COX-2 inhibitory analog of celecoxib. Blood 106(13):4330–4338CrossRefPubMedGoogle Scholar
  36. Kashfi K, Rigas B (2005) Is COX-2 a ‘collateral’ target in cancer prevention? Biochem Soc Trans 33(Pt 4):724–727PubMedGoogle Scholar
  37. Kashfi K, Rigas B (2007) The mechanism of action of nitric oxide-donating aspirin. Biochem Biophys Res Commun 358(4):1096–1101CrossRefPubMedGoogle Scholar
  38. Klaunig JE, Kamendulis LM (2004) The role of oxidative stress in carcinogenesis. Annu Rev Pharmacol Toxicol 44:239–267CrossRefPubMedGoogle Scholar
  39. Konduri S et al (2009) Tolfenamic acid enhances pancreatic cancer cell and tumor response to radiation therapy by inhibiting survivin protein expression. Mol Cancer Ther 8(3):533–542CrossRefPubMedGoogle Scholar
  40. Kusuhara H et al (1998) Induction of apoptotic DNA fragmentation by nonsteroidal anti-inflammatory drugs in cultured rat gastric mucosal cells. Eur J Pharmacol 360(2–3):273–280CrossRefPubMedGoogle Scholar
  41. Lefebvre AM et al (1998) Activation of the peroxisome proliferator-activated receptor gamma promotes the development of colon tumors in C57BL/6 J-APCMin/+ mice. Nat Med 4(9):1053–1057CrossRefPubMedGoogle Scholar
  42. Lehmann JM et al (1997) Peroxisome proliferator-activated receptors alpha and gamma are activated by indomethacin and other non-steroidal anti-inflammatory drugs. J Biol Chem 272(6):3406–3410CrossRefPubMedGoogle Scholar
  43. Li F (2005) Role of survivin and its splice variants in tumorigenesis. Br J Cancer 92(2):212–216PubMedGoogle Scholar
  44. Lincoln TM, Cornwell TL (1993) Intracellular cyclic GMP receptor proteins. Faseb J 7(2):328–338PubMedGoogle Scholar
  45. Ljungdahl S, Shoshan MC, Linder S (1997) Inhibition of the growth of 12 V-ras-transformed rat fibroblasts by acetylsalicylic acid correlates with inhibition of NF-kappa B. Anticancer Drugs 8(1):62–66CrossRefPubMedGoogle Scholar
  46. Ma L, Teruya-Feldstein J, Weinberg RA (2007) Tumour invasion and metastasis initiated by microRNA-10b in breast cancer. Nature 449(7163):682–688CrossRefPubMedGoogle Scholar
  47. Ma L et al (2010a) Therapeutic silencing of miR-10b inhibits metastasis in a mouse mammary tumor model. Nat Biotechnol 28(4):341–347CrossRefPubMedGoogle Scholar
  48. Ma L et al (2010b) MiR-9, a MYC/MYCN-activated microRNA, regulates E-cadherin and cancer metastasis. Nat Cell Biol 12(3):247–256PubMedGoogle Scholar
  49. Mackenzie GG et al (2010) Phospho-sulindac (OXT-328), a novel sulindac derivative, is safe and effective in colon cancer prevention in mice. Gastroenterology 139(4):1320–1332CrossRefPubMedGoogle Scholar
  50. Mueller E et al (1998) Terminal differentiation of human breast cancer through PPAR gamma. Mol Cell 1(3):465–470CrossRefPubMedGoogle Scholar
  51. Nakajima G et al (2006) Non-coding microRNAs hsa-let-7 g and hsa-miR-181b are associated with chemoresponse to S-1 in colon cancer. Cancer Genomics Proteomics 3(5):317–324PubMedGoogle Scholar
  52. Oshima M et al (1996) Suppression of intestinal polyposis in Apc delta716 knockout mice by inhibition of cyclooxygenase 2 (COX-2). Cell 87(5):803–809CrossRefPubMedGoogle Scholar
  53. Piazza GA et al (1995) Antineoplastic drugs sulindac sulfide and sulfone inhibit cell growth by inducing apoptosis. Cancer Res 55(14):3110–3116PubMedGoogle Scholar
  54. Piazza GA et al (1997a) Apoptosis primarily accounts for the growth-inhibitory properties of sulindac metabolites and involves a mechanism that is independent of cyclooxygenase inhibition, cell cycle arrest, and p53 induction. Cancer Res 57(12):2452–2459PubMedGoogle Scholar
  55. Piazza GA et al (1997b) Sulindac sulfone inhibits azoxymethane-induced colon carcinogenesis in rats without reducing prostaglandin levels. Cancer Res 57(14):2909–2915PubMedGoogle Scholar
  56. Piazza GA et al (2009) A novel sulindac derivative that does not inhibit cyclooxygenases but potently inhibits colon tumor cell growth and induces apoptosis with antitumor activity. Cancer Prev Res (Phila Pa) 2(6):572–580CrossRefGoogle Scholar
  57. Pyrko P et al (2006) Downregulation of survivin expression and concomitant induction of apoptosis by celecoxib and its non-cyclooxygenase-2-inhibitory analog, dimethyl-celecoxib (DMC), in tumor cells in vitro and in vivo. Mol Cancer 5:19CrossRefPubMedGoogle Scholar
  58. Rayet B, Gelinas C (1999) Aberrant rel/nfkb genes and activity in human cancer. Oncogene 18(49):6938–6947CrossRefPubMedGoogle Scholar
  59. Rigas B, Kashfi K (2004) Nitric-oxide-donating NSAIDs as agents for cancer prevention. Trends Mol Med 10(7):324–330CrossRefPubMedGoogle Scholar
  60. Rigas B, Kozoni V (2008) The novel phenylester anticancer compounds: Study of a derivative of aspirin (phoshoaspirin). Int J Oncol 32(1):97–100PubMedGoogle Scholar
  61. Rigas B, Williams JL (2008) NO-donating NSAIDs and cancer: an overview with a note on whether NO is required for their action. Nitric Oxide 19(2):199–204CrossRefPubMedGoogle Scholar
  62. Saez E et al (1998) Activators of the nuclear receptor PPARgamma enhance colon polyp formation. Nat Med 4(9):1058–1061CrossRefPubMedGoogle Scholar
  63. Sawaoka H et al (1998) Effects of NSAIDs on proliferation of gastric cancer cells in vitro: possible implication of cyclooxygenase-2 in cancer development. J Clin Gastroenterol 27(Suppl 1):S47–S52CrossRefPubMedGoogle Scholar
  64. Schwenger P et al (1998) Activation of p38 mitogen-activated protein kinase by sodium salicylate leads to inhibition of tumor necrosis factor-induced IkappaB alpha phosphorylation and degradation. Mol Cell Biol 18(1):78–84PubMedGoogle Scholar
  65. Shailubhai K et al (2000) Uroguanylin treatment suppresses polyp formation in the Apc(Min/+) mouse and induces apoptosis in human colon adenocarcinoma cells via cyclic GMP. Cancer Res 60(18):5151–5157PubMedGoogle Scholar
  66. Shiff SJ, Rigas B (1999) The role of cyclooxygenase inhibition in the antineoplastic effects of nonsteroidal antiinflammatory drugs (NSAIDs). J Exp Med 190(4):445–450CrossRefPubMedGoogle Scholar
  67. Silvola J et al (1982) Effects of nonsteroidal anti-inflammatory drugs on rat gastric mucosal phosphodiesterase activity. Agents Actions 12(4):516–520CrossRefPubMedGoogle Scholar
  68. Soh JW et al (2000) Cyclic GMP mediates apoptosis induced by sulindac derivatives via activation of c-Jun NH2-terminal kinase 1. Clin Cancer Res 6(10):4136–4141PubMedGoogle Scholar
  69. Soh JW et al (2008) Celecoxib-induced growth inhibition in SW480 colon cancer cells is associated with activation of protein kinase G. Mol Carcinog 47(7):519–525CrossRefPubMedGoogle Scholar
  70. Song B et al (2010) MicroRNA-21 regulates breast cancer invasion partly by targeting tissue inhibitor of metalloproteinase 3 expression. J Exp Clin Cancer Res 29:29CrossRefPubMedGoogle Scholar
  71. Sonnenburg WK, Beavo JA (1994) Cyclic GMP and regulation of cyclic nucleotide hydrolysis. Adv Pharmacol 26:87–114CrossRefPubMedGoogle Scholar
  72. Steinbach G et al (2000) The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis. N Engl J Med 342(26):1946–1952CrossRefPubMedGoogle Scholar
  73. Sun Y et al (2011) Oxidative stress mediates through apoptosis the anticancer effect of phospho-NSAIDs: implications for the role of oxidative stress in the action of anticancer agents. J Pharmacol Exp Ther 338(3):775–783CrossRefPubMedGoogle Scholar
  74. Thompson WJ et al (2000) Exisulind induction of apoptosis involves guanosine 3’,5’-cyclic monophosphate phosphodiesterase inhibition, protein kinase G activation, and attenuated beta-catenin. Cancer Res 60(13):3338–3342PubMedGoogle Scholar
  75. Thun MJ, Henley SJ, Patrono C (2002) Nonsteroidal anti-inflammatory drugs as anticancer agents: mechanistic, pharmacologic, and clinical issues. J Natl Cancer Inst 94(4):252–266CrossRefPubMedGoogle Scholar
  76. Tinsley HN et al (2009) Sulindac sulfide selectively inhibits growth and induces apoptosis of human breast tumor cells by phosphodiesterase 5 inhibition, elevation of cyclic GMP, and activation of protein kinase G. Mol Cancer Ther 8(12):3331–3340CrossRefPubMedGoogle Scholar
  77. Tinsley HN et al (2010) Colon tumor cell growth-inhibitory activity of sulindac sulfide and other nonsteroidal anti-inflammatory drugs is associated with phosphodiesterase 5 inhibition. Cancer Prev Res (Phila) 3(10):1303–1313CrossRefGoogle Scholar
  78. Tinsley HN et al (2011) Inhibition of PDE5 by Sulindac Sulfide Selectively Induces Apoptosis and Attenuates Oncogenic Wnt/{beta}-Catenin-Mediated Transcription in Human Breast Tumor Cells. Cancer Prev Res (Phila) 4(8):1275–1284CrossRefGoogle Scholar
  79. Toyokuni S et al (1995) Persistent oxidative stress in cancer. FEBS Lett 358(1):1–3CrossRefPubMedGoogle Scholar
  80. Tsujii M et al (1998) Cyclooxygenase regulates angiogenesis induced by colon cancer cells. Cell 93(5):705–716CrossRefPubMedGoogle Scholar
  81. Vane JR, Botting RM (1998) Mechanism of action of antiinflammatory drugs. Int J Tissue React 20(1):3–15PubMedGoogle Scholar
  82. Vane JR, Bakhle YS, Botting RM (1998) Cyclooxygenases 1 and 2. Annu Rev Pharmacol Toxicol 38:97–120CrossRefPubMedGoogle Scholar
  83. Warner TD et al (1999) Nonsteroid drug selectivities for cyclo-oxygenase-1 rather than cyclo-oxygenase-2 are associated with human gastrointestinal toxicity: a full in vitro analysis. Proc Natl Acad Sci U S A 96(13):7563–7568CrossRefPubMedGoogle Scholar
  84. Williams JL et al (2004) NO-donating aspirin inhibits intestinal carcinogenesis in Min (APC(Min/+)) mice. Biochem Biophys Res Commun 313(3):784–788CrossRefPubMedGoogle Scholar
  85. Xi Y et al (2006) Prognostic values of microRNAs in colorectal cancer. Biomark Insights 2:113–121PubMedGoogle Scholar
  86. Xie G et al (2011) Phospho-ibuprofen (MDC-917) is a novel agent against colon cancer: efficacy, metabolism, and pharmacokinetics in mouse models. J Pharmacol Exp Ther 337(3):876–886CrossRefPubMedGoogle Scholar
  87. Yeh RK et al (2004) NO-donating nonsteroidal antiinflammatory drugs (NSAIDs) inhibit colon cancer cell growth more potently than traditional NSAIDs: a general pharmacological property? Biochem Pharmacol 67(12):2197–2205CrossRefPubMedGoogle Scholar
  88. Yin MJ, Yamamoto Y, Gaynor RB (1998) The anti-inflammatory agents aspirin and salicylate inhibit the activity of I(kappa)B kinase-beta. Nature 396(6706):77–80CrossRefPubMedGoogle Scholar
  89. Yu Z et al (2010) MicroRNA 17/20 inhibits cellular invasion and tumor metastasis in breast cancer by heterotypic signaling. Proc Natl Acad Sci U S A 107(18):8231–8236CrossRefPubMedGoogle Scholar
  90. Zaffaroni N, Pennati M, Daidone MG (2005) Survivin as a target for new anticancer interventions. J Cell Mol Med 9(2):360–372CrossRefPubMedGoogle Scholar
  91. Zhu B et al (2005) Suppression of cyclic GMP-specific phosphodiesterase 5 promotes apoptosis and inhibits growth in HT29 cells. J Cell Biochem 94(2):336–350CrossRefPubMedGoogle Scholar
  92. Zhu S et al (2008) MicroRNA-21 targets tumor suppressor genes in invasion and metastasis. Cell Res 18(3):350–359CrossRefPubMedGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2013

Authors and Affiliations

  • Heather N. Tinsley
    • 1
  • William E. Grizzle
    • 2
  • Ashraf Abadi
    • 3
  • Adam Keeton
    • 4
  • Bing Zhu
    • 4
  • Yaguang Xi
    • 4
  • Gary A. Piazza
    • 4
  1. 1.Department of Biology, Chemistry, and MathematicsUniversity of MontevalloMontevalloUSA
  2. 2.Department of PathologyThe University of Alabama at BirminghamBirminghamUSA
  3. 3.Faculty of Pharmacy and BiotechnologyGerman University of CairoCairoEgypt
  4. 4.Drug Discovery Research Center Mitchell Cancer InstituteUniversity of South AlabamaMobileUSA

Personalised recommendations